Artesunate
- Generic Name
- Artesunate
- Brand Names
- Artesunate Amivas
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28O8
- CAS Number
- 88495-63-0
- Unique Ingredient Identifier
- 60W3249T9M
Overview
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin. Artesunate was granted FDA approval on 26 May 2020.
Background
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of artemisinin. Artesunate was granted FDA approval on 26 May 2020.
Indication
Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients.
Associated Conditions
- Acute Uncomplicated Plasmodium Falciparum Malaria
- Malaria, Cerebral
- Severe Malaria
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.